STANDARD &POOR'S

Setting the Standard



Rating Compliance & Corporate Responsibility

Presentation to 5th Annual Pharmaceutical Regulatory & Compliance Congress

> By: Andrea M. Esposito Managing Director America's Practice Leader Governance Services November 17th, 2004

The **McGraw**·Hill Companies

Ongoing Initiatives to Enhance Standard & Poor's Analytics

Accounting

Analytical Training

Surveillance Enhancement

Management & Governance

Risk Management Enhancement

Policy & Review Control Practices

Corporate Governance Analysis

At its most basic level –

it is the interaction of a company's

management
board directors
shareholders

to direct and control the company to ensure that all financial stakeholders (shareholders and creditors) receive their fair share of the company's earnings and assets

In 1998, Standard & Poor's researched and developed criteria to review companies governance.



Corporate Governance Analysis

- Historically, management & governance have been factored into ratings
- □ Today, identifying risk factors is more structured and systematic
 - Enhancing rigor of credit committee discussions
 - Increasing disclosure via publication
- Common element of corporate failures is a heightened risk profile
 - > Aggressive management culture
 - Weak board oversight
- A combination of risk factors can be symptomatic of a heightened risk profile and can result in an incremental governance review

Corporate Governance Analytical Framework

Weak corporate governance:

- Allows:
 - > Inappropriate allocation of corporate resources
 - Management incentives that can compromise long-term stability
 - Inadequate oversight of the integrity of financial disclosure
- Undermines creditworthiness

Leads to heightened funding and liquidity risk

Pharmaceutical Manufacturers Rated by S&P

35 Pharmaceutical Manufacturers are rated

17 are investment grade including the big eight

- Abbott Laboratories Inc
- Bristol-Myers Squibb Co.
- Eli Lilly & Co.
- Johnson & Johnson

- Merck & Co. Inc.
- Pfizer Inc.
- Schering Plough Corp.

Wyeth

Problems facing the Pharmaceutical Industry

Pricing pressures

- Large & inefficient R&D programs
- Empty near term R&D pipelines
- Patent expirations
- Public furor of rising drug costs,
- Pressures from HMOs
- Marketing scandals & record fines
- Accounting improprieties

Standard & Poor's

Problems facing the Pharmaceutical Industry

Lack of new products to drive growth



more aggressive promotion of existing products to marketing violations and record fines.

Under-investment in maintaining manufacturing facilities in full compliance and stricter FDA manufacturing standards several manufacturing noncompliance issues resulting in:

Product delays

Product withdrawals

Loss of market share

□Major fines

Drain on resources

Corporate Governance Analytical Framework

繡

Inf Tra Co	wnership Structure & External fluence ansparency of ownership oncentration and influence of wnership & external stakeholders	3. □ □	Transparency, Disclosure & Audit Content of public disclosure Timing of, and access to, public disclosure Audit process
Si D D D	hareholder Rights and takeholders Relations hareholder Meeting & Voting rocedures wnership Rights & Takeover efenses takeholder Relations	4. □ □ □	Board Structure and Effectiveness Board structure and independence Role & effectiveness of board Senior Executive & director compensation



Standard & Poor's assesses the audit process at the board level.

Outsiders want to know what processes are in place for managing risk inside the company.

We assess the processes by which internal control & risk management strategies and accounting policy choices are made and the sufficiency of oversight of this process.



□This assessment is often driven by our interviews with:

- □audit committee members,
- □the internal audit team, and
- the lead partner from the company's outside auditor.



Our discussions with audit committee members reflect their:

- knowledge of and oversight of the company's financial statements, internal controls and risk management procedures.
- articulation on how major risks to the business are monitored, and on how they respond as directors as risks and risk tolerances change

Audit Process



"Oh, that three billion dollars."

Corporate Governance Analytical framework Board structure and effectiveness

Board Composition and Independence

- Board size and structure
- Skill mix, diversity, experience
- Chair/CEO split
- Director selection
- Director shareholdings
- Board Independence
- Board committees and committee composition
- Director nominations and tenure

Role & Effectiveness of the Board

- Lines of responsibility
- Reporting systems
- Setting company purpose, mission and ethical parameters
- Strategy setting, board cohesiveness
- Management appointment, oversight & succession
- Monitoring internal control & risk management
- Self-evaluation/training
- Meeting frequency and attendance/external commitments

Senior Executive & Director Compensation

- Link of pay to performance
- Who determines compensation?
- Compensation policy and comparators
- Compensation consultant relationship
- Cash/share balance (senior management)
- Stock options (management and directors)
- Compensation disclosure
- Executive contracts
- Dilution overhang
- Perks and other benefits

Standard & Poor's

Corporate Governance Analysis Board Structure and Effectiveness

□Frames the <u>balance of power</u> between



Is subjective - Addresses qualitative concerns

Concerns invisible to public disclosure

Captures board atmosphere & internal dynamics
Integrity - Independence - Teamwork

Corporate Governance Score Board Structure and Effectiveness

Director's <u>"Independence of Mind"</u> from:

- > Chairman
- ≻CEO
- Other board members

Going beyond the simple appearance of independence

"Independence of mind" is reflected in:

- Engagement
- Being well informed
- Having diverse skill sets and perspectives

Corporate Governance Score Board Structure and Effectiveness

An effective board avoids:

Fractious behaviour,

but not

Constructive conflict or

> Differences of opinion

Corporate Governance Score



"What we didn't have but obviously needed was an alarmist."

Executive Compensation

- □ Is pay linked to real increases in company performance?
- Executive contracts and severance agreements are examined to determine the structure of specific pay packages and the incentives embedded within them
- Is pay distributed over several forms with different measures, restricting opportunities to "game" the system
- Who owns the relationship with the outside compensation consultants?
- Standard & Poor's evaluates and benchmarks the dilutive effective of equity-linked awards to the company's peers

Contact Information

Andrea M. Esposito

Managing Director & Americas' Governance Services Region Head

Standard & Poor's

212-438-6520

andrea_esposito@standardandpoors.com